Opinion/decision on a Paediatric investigation plan (PIP): Zeposia,Ozanimod (hydrochloride), decision type: , therapeutic area: , PIP number: P/0392/2022
Opinion/decision on a Paediatric investigation plan (PIP): Crysvita,Burosumab, decision type: , therapeutic area: , PIP number: P/0411/2022
Compilation of Union procedures on inspections and exchange of information
CTIS newsflash - 15 September 2023
Network Portfolio Roadmap 2023-2025
List of industry subject matter experts and list of planned calls for industry subject matter experts
Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies
Report on the implementation of the EMA-EUnetHTA 21 work plan 2021 - 2023
Recommendation for maintenance of orphan designation at the time of addition of new indications to the marketing authorisation: Votubia (everolimus) for the treatment of tuberous sclerosis
Management Board meeting: 7-8 June 2023, European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2023 to 08/06/2023